AbCellera Biologics (ABCL) Interest & Investment Income (2022 - 2026)

AbCellera Biologics has reported Interest & Investment Income for 5 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 34.04% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $23.9 million (down 28.8% YoY), and the FY2025 full-year result was $28.3 million, down 26.37% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $3.6 million, down from $5.9 million in the prior quarter.
• The five-year high for Interest & Investment Income was $11.0 million in Q4 2023, with the low at $665000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $7.4 million across 5 years, with a median of $8.5 million in 2022.
• Annual changes were most pronounced in 2023 — Interest & Investment Income jumped 1367.52% — and 2025, when it slumped 46.9%.
• AbCellera Biologics' Interest & Investment Income stood at $8.5 million in 2022, then grew by 29.5% to $11.0 million in 2023, then fell by 20.98% to $8.7 million in 2024, then slumped by 31.7% to $5.9 million in 2025, then plunged by 38.46% to $3.6 million in 2026.
• The last three Interest & Investment Income figures came in at $3.6 million (Q1 2026), $5.9 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.